DelveInsight’s “Acute Heart Failure Market Insight, Epidemiology and Market Forecast 2032” report provides current treatment practices, emerging drugs, Acute Heart Failure market share of the individual therapies, current and forecasted Acute Heart Failure market size from 2019 to 2032 segmented by seven major markets. The report also offers current Acute Heart Failure therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute Heart Failure market.

 

Acute Heart Failure Overview

Heart Failure (HF) is also known as congestive heart failure. It is also bifurcated as left-side HF (when the heart is unable to pump enough oxygen in the blood to the body) and right-side HF (when the heart is unable to fill itself with enough blood). Another term for HF is corpulmonale which means that right-side HF is caused by high blood pressure in the pulmonary arteries and right ventricle.

There are two types of heart failure: acute and chronic. Acute heart failure has a sudden onset and symptoms can appear without warning. However, in chronic heart failure, that difficulty is ongoing and long-term. It was observed that majority of patients are affected with Chronic heart failure. Acute heart failure (AHF) is a kind of syndrome that is defined as the new onset (de novo heart failure (HF)) or worsening (acutely decompensated heart failure (ADHF)) of symptoms and signs of HF, mostly related to systemic congestion. 

The clinical presentation of AHF is characterized mostly by symptoms and signs related to systemic congestion (that is, extracellular fluid accumulation, initiated by increased biventricular cardiac filling pressures). Symptoms of acute heart failure include: Shortness of breath while moving or lying flat, also known as dyspnea, Feeling tired, Swelling of feet, ankles, legs, abdomen or veins in the neck, among others.

 

Acute Heart Failure Epidemiological Insights

According to the study conducted by Mozaffarian et al. (2015), acute heart failure constitutes the first reason for hospital admission in the elderly, with a total of approximately 1 million admissions per year in the US and a similar number in Europe.

 

Acute Heart Failure Treatment Market 

Congestive HF is a morbidity that is increasing worldwide due to the aging population and improvement in (acute) care for patients with cardiovascular diseases. The prognosis for patients with HF is very poor without treatment. Furthermore, hospitalizations for cardiac decompensation cause an increasing economic burden. It is a chronic long-term condition that gets worse with time. There are four stages of heart failure (Stage A, B, C and D). The stages range from “high risk of developing heart failure” to “advanced heart failure,” and provide treatment plans. These stages are different from the New York Heart Association (NYHA) clinical classifications of heart failure (Class I-II-III-IV) that reflect the severity of symptoms or functional limits due to heart failure (Cowie, 2017)(Tanaka, Sawano, Ramani, Friedman, & Kohsaka, 2018).

Globally, acute heart failure (AHF) remains an ongoing public health issue with its prevalence and mortality increasing in the east and the west. Almost 6 million Americans have heart failure, and there are an additional 500,000 new cases diagnosed each year. 

According to the Centers for Disease Control and Prevention (CDC), about 5.7 million adults in the United States have heart failure. Heart failure happens when the heart cannot pump enough blood and oxygen to support other organs in the body. Heart failure is a serious condition, but it does not mean that the heart has stopped beating. About half of people who develop heart failure die within 5 years of diagnosis.

Acute heart failure can be severe and anyone with symptoms should see a clinician as soon as possible. Treatment is initially focused on alleviating life-threatening symptoms, then on the examination of underlying causes and treatment of residual symptoms. Hospitalization is generally required while cardiac performance improves. There are a range of potential treatments for acute heart failure. The treatment that is applied will depend on the person’s symptoms and the underlying issue causing them. For an instance Shortness of breath (dyspnea): This symptom is treated with supplemental oxygen. The severity of dyspnea will dictate whether oxygen is supplied through a tube in the nose or a face mask. Sitting upright can help with breathing. Buildup of fluid: Intravenous diuretics are used to treat buildup of fluid within the body. A pulmonary edema will also be treated with diuretics, as well as oxygen and heart failure medication.

 

Promising Therapies in the Acute Heart Failure Pipeline

• Empagliflozin
• Forxiga
• APD418
• And others

 

Discover more about Acute Heart Failure therapies in the pipeline @ Acute Heart Failure Drugs

 

Leading Companies Working in the Acute Heart Failure Market

• Boehringer Ingelheim
• Eli Lilly and Company
• AstraZeneca
• And others

 

To understand key companies related to the  Acute Heart Failure Market, get a snapshot of the Acute Heart Failure Regulatory and Patent Analysis.

 

Scope of the Acute Heart Failure Market Report

Study Period: 2019–2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]

Key Acute Heart Failure Companies: Boehringer Ingelheim, Eli Lilly and Company, AstraZeneca, and others

Key Acute Heart Failure Pipeline Therapies: Empagliflozin, Forxiga, APD418, and others

Therapeutic Assessment: Acute Heart Failure current marketed and emerging therapies

Acute Heart Failure Market Dynamics: Acute Heart Failure market drivers and barriers 

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

Unmet Needs, KOL’s views, Analyst’s views, Acute Heart Failure Market Access and Reimbursement

 

Table of Contents

1. Acute Heart Failure Market Key Insights

2. Acute Heart Failure Market Report Introduction

3. Acute Heart Failure Market Overview at a Glance

4. Acute Heart Failure Market Executive Summary

5. Disease Background and Overview

6. Acute Heart Failure Treatment and Management

7. Acute Heart Failure Epidemiology and Patient Population

8. Patient Journey

9. Acute Heart Failure Emerging Drugs

10. 7MM Acute Heart Failure Market Analysis

11. Acute Heart Failure Market Outlook

12. Potential of Current and Emerging Therapies

13. KOL Views

14. Acute Heart Failure Market Drivers

15. Acute Heart Failure Market Barriers

16. Unmet Needs

17. SWOT Analysis

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

Trending Report Offerings by DelveInsight:

• Gender Dysphoria Market
• Germany Healthcare Outlook Market
• Hyperlipidemia Market
• Mammography Devices Market
• Dental Equipment Market
• Adalimumab Biosimilar Market
• Hyperlipidemia Market
• Metastatic Cutaneous Squamous Cell Cancer Market
• Mucopolysaccharidosis Market

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

 

Contact Us

Kritika Rehani

info@delveinsight.com 

+1(919)321-6187 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/